A US key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.
SKU: N/A
Author: Datamonitor Healthcare
Publisher: Biomedtracker
Published: 25 January 2019
Number of pages:14
Formats:PDF
Report code:TL #10145
Highlights
Description
Highlights
“Symtuza, of course, I use that as well, again a high barrier to resistance, well tolerated, good efficacy. The problem with Symtuza is that sometimes it has more drug interactions than I have with Biktarvy, andsometimes I just get concerned about using a protease inhibitor, and perhaps a little bit of an impact on the bits associated with that, and also darunavir has an increased risk for myocardial infarction.
“Very favorable [thoughts on Biktarvy], I use it a lot, it is probably the regimen I use the most, if anything. It is well tolerated, it has good outcomes, I have seen patients with really no significant problems, very favorable drug interactions profile.”
“Zero resistance reported is a huge advantage, I mean that gives me a lot of confidence that I can use it [Biktarvy] in a wide range of patients without concern that they develop resistance. It is unboosted, which is also another big advantage, I do not have to worry about impact at all on hepatic function.”
Overview
A US key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.